Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Sensex Trades in Red; FMCG Stocks Witness Selling
Wed, 2 Aug 01:30 pm

After opening the day marginally higher, share markets in India witnessed cautious trading activity eyeing the RBI monetary policy decision scheduled today, and are presently trading marginally below the dotted line. Sectoral indices are trading on a mixed note with stocks in the power sector and consumer durables sector witnessing maximum buying interest. Metals stocks and FMCG sector are trading in the red.

The BSE Sensex is trading down by 50 points (down 0.2%) and the NSE Nifty is trading down by 24 points (down 0.2%). The BSE Mid Cap index is trading down by 0.3%, while the BSE Small Cap index is trading up by 0.2%. The rupee is trading at 63.91 to the US$.

In news from stocks in the pharma sector, Lupin is in focus today after the pharma major received US Food and Drug Administration (USFDA) approval to market Fluocinonide Topical ointment, an anti-inflammatory drug, in the American market.

The ointment is a generic version of County Line Pharmaceuticals' Lidex ointment and is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Citing IMS MAT sales data, the company said that Lidex had sales of US$ 40.3 million in the US market till March 2017.

Lupin has so far received approval for 220 products and is still awaiting USFDA nods for 148 more products.

Recently, the drugmaker's Aurangabad manufacturing plant underwent USFDA inspection. During the inspection, the US Food and Drug administration (USFDA) issued one 483 observation. The company said that the observation was procedural and would be corrected during the inspection itself.

Just Released: Multibagger Stocks Guide
(2017 Edition)

In this report, we reveal four proven strategies to picking multibagger stocks.

Well over a million copies of this report have already been claimed over the years.

Go ahead, grab your copy today. It's Free.

NO-SPAM PLEDGE - We will NEVER rent, sell, or give away your e-mail address to anyone for any reason. You can unsubscribe from The 5 Minute WrapUp with a few clicks. Please read our Privacy Policy & Terms Of Use.

As per USFDA, observations are made in Form 483 when investigators feel that conditions or practices in the facility are such that products may become adulterated or render injuries to health.

In recent times, pharma companies have been bogged down by mounting pressure from US Food and Drug Administration (USFDA) to adhere to quality standards at their manufacturing plants. In the past three years, the USFDA raised numerous regulatory concerns resulting in import bans and suspension of new drug approvals from facilities of Indian pharma companies.

However, new drug approvals are seen to pick up sharply in 2017.

USFDA sweetener for Indian Pharma

During the period January-July 2017, 129 approvals for generic drugs were made. This is 45% higher from 89 approvals made in the corresponding period last year.

As per the Indian Pharmaceutical Alliance, the pace of drug approvals has gained momentum after they complained to FDA about delays last year. Approvals for drugs have also picked up after USFDA concerns at some of the manufacturing units were addressed.

The USFDA's move to speed up generic drug approvals in a bid to reduce healthcare costs is likely to provide some earnings relief to domestic pharma companies.

At the time of writing, Lupin share price was trading up by 2.5%.

Moving on to news from stocks in the FMCG sector. Marico opened the day lower by 5% today after it posted tepid results for the June quarter.

Marico reported a 12% fall in the quarter's net profit at Rs 2.36 billion as against Rs 2.68 billion posted in the same period last year.

The FMCG major saw a 4% drop in its consolidated revenue, owing mostly due to a dip in its volumes, which were down by over 9% in the quarter.

The company attributed the volume fall to de-stocking effect in June due to Goods and Services Tax (GST). The company also said that the decline is attributable to steep pipeline correction.

The company further said that it held back price increase in Parachute rigid portfolio due to GST rollout.

At the time of writing, Marico share price was trading down by 1.8%.

On the corporate earnings front, the GST implementation is said to impact near term earnings of the companies. However, over a long run, expectations are that earnings would normalize. In addition, GST is expected to be a big support to the depressed earnings of the organised listed Indian companies in the long run.

However, GST is a complicated topic, the exact implications of which will be obvious over next few years. Vivek Kaul, editor of Vivek Kaul's Diary has studied the finer aspects of GST and predicted what could go right and wrong.

To know more, download his special report - The Good, the Sad and the Terrible (GST)

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Sensex Trades in Red; FMCG Stocks Witness Selling". Click here!


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Feb 23, 2018 (Close)